MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2016.11.426 ◽

2017 ◽

Vol 12 (1) ◽

pp. S378 ◽

Author(s):

D. Ross Camidge ◽

Shirish Gadgeel ◽

Sai-Hong Ou ◽

Leena Gandhi ◽

Gregory Riely ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Safety Data ◽

Phase 2 ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Download Full-text

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.03.007 ◽

2019 ◽

Vol 14 (7) ◽

pp. 1233-1243 ◽

Author(s):

D. Ross Camidge ◽

Rafal Dziadziuszko ◽

Solange Peters ◽

Tony Mok ◽

Johannes Noe ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Safety Data ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Download Full-text

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

ESMO Open ◽

10.1016/j.esmoop.2021.100333 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100333

Author(s):

J. Wolf ◽

Å. Helland ◽

I.-J. Oh ◽

M.R. Migliorino ◽

R. Dziadziuszko ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Safety Data ◽

Molecular Profiling ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Download Full-text

Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study

10.1055/s-0039-1678065 ◽

2019 ◽

Author(s):

DP Carbone ◽

D Morgensztern ◽

S Le Moulec ◽

R Santana-Davila ◽

N Ready ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 2 ◽

Efficacy And Safety ◽

Small Cell Lung

Download Full-text

Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

PLoS ONE ◽

10.1371/journal.pone.0114008 ◽

2014 ◽

Vol 9 (12) ◽

pp. e114008 ◽

Author(s):

Yabing Cao ◽

Guangli Xiao ◽

Xibin Qiu ◽

Sheng Ye ◽

Tongyu Lin

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Advanced Stage ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Download Full-text

MA02.01 Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.111 ◽

2021 ◽

Vol 16 (10) ◽

pp. S888-S889

Author(s):

S. Lu ◽

Y. Cheng ◽

D. Huang ◽

Y. Sun ◽

L. Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Chinese Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Download Full-text

Erlotinib (ERL) versus Pemetrexed (MTA) as Second-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): Efficacy and Safety Data

Annals of Oncology ◽

10.1016/s0923-7534(20)33804-7 ◽

2012 ◽

Vol 23 ◽

pp. ix438-ix439

Author(s):

J. Zugazagoitia ◽

J. Puente ◽

S. Hernandez ◽

J.L. Gonzalez-Larriba ◽

J. Sanz ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Safety Data ◽

Line Treatment ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung

Download Full-text

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2014.08.216 ◽

2014 ◽

Vol 90 (5) ◽

pp. S37-S38 ◽

Author(s):

H.A. Wakelee ◽

Z. Zvirbule ◽

F. De Braud ◽

C.D. Kingsley ◽

T. Mekhail ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Download Full-text

Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”

Journal of Thoracic Disease ◽

10.21037/jtd.2016.10.57 ◽

2016 ◽

Vol 8 (10) ◽

pp. E1287-E1292 ◽

Author(s):

Ivana Sullivan ◽

David Planchard

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Download Full-text

Phase 2 study evaluating efficacy and safety of everolimus with letrozole in advanced (unresectable or metastatic) non-small cell lung cancer (NSCLC) after failure of platinum-based treatment: A preliminary analysis of toxicity.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e19089 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e19089-e19089

Author(s):

Sina Vatandoust ◽

Nimit Singhal ◽

Michael Paul Brown

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Preliminary Analysis ◽

Phase 2 ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Download Full-text

Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

Annals of Oncology ◽

10.1093/annonc/mdz243 ◽

2019 ◽

Vol 30 ◽

pp. v143-v144 ◽

Author(s):

F. Barlesi ◽

D.-W. Kim ◽

E.M. Bertino ◽

M.J. van den Bent ◽

H. Wakelee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Leptomeningeal Metastases ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Alk Positive ◽

Download Full-text